# Pawarate_Vhaiprom_CRISPRCas9_IARCO2025 - Pawarate Vhaiprom.pdf

*by* Sanaul Haque

**Submission date:** 13-Oct-2025 11:09PM (UTC+0700)
**Submission ID:** 2779950419
**File name:** Pawarate_Vhaiprom_CRISPRCas9_IARCO2025_-_Pawarate_Vhaiprom.pdf (424.59K)
**Word count:** 2440
**Character count:** 14637

| | |
|---|---|
| **Full Name** | Pawarate Vhaiprom |
| **Institution Name** | Sirindhorn School |
| **Country** | Thailand |
| **Category** | Junior |
| **Class/Year** | Grade 12 (M.6) |
| **Major/Subjects** | Biology |
| **Registered Email Address** | Autopawarate51@gmail.com |
| **Submission Date** | September 30, 2025 |


# From Bacterial Defense to Human Therapy: A Theoretical Exploration of CRISPR-Cas9 in Biomedical Innovation


## Abstract

First identified as a bacterial defense system, CRISPR-Cas9 has emerged as the most widely used genome-editing platform due to its simplicity, programmability, and broad biomedical applications. By combining a guide RNA with the Cas9 nuclease, the system can locate and cleave specific DNA sequences, enabling targeted modifications at the molecular level. This theoretical study explores the transition of CRISPR from microbial immunity to human therapy, emphasizing its potential to reshape the treatment of genetic disorders. Key therapeutic examples include ex vivo editing of hematopoietic stem cells to treat sickle cell disease, engineering of immune cells for cancer immunotherapy, and in vivo correction of retinal mutations causing inherited blindness. Advances such as base editing and prime editing further expand the toolkit, providing greater precision while reducing reliance on double-stranded DNA breaks. Nonetheless, significant challenges remain, including delivery barriers, risks of unintended edits, and ethical concerns surrounding equitable access and germline modification. Through synthesizing current scientific evidence into clear conceptual frameworks, this paper highlights CRISPR-Cas9 as both a transformative tool and a platform requiring responsible development.


## Introduction

Since its discovery as a bacterial defense system, CRISPR-Cas9 has captured global attention as one of the most powerful tools in modern biology. By combining a guide RNA with the Cas9 nuclease, the system can cut DNA at specific locations with remarkable accuracy, transforming a natural immune mechanism into a programmable gene-editing platform [1]. In less than a decade, CRISPR-Cas9 has become the most widely used genome-editing system, driving advances in agriculture, biotechnology, and medicine. Clinical trials are already testing its ability to correct genetic disorders such as sickle cell disease, inherited blindness, and cancer [2]. Yet this rapid rise also exposes unresolved problems: risks of unintended edits, barriers to efficient delivery, and ethical concerns about human germline modification [3]. The key challenge is balancing CRISPR-Cas9's revolutionary potential with the technical and ethical responsibilities it entails. This study positions the technology as both a transformative tool and a platform requiring responsible development. To support this claim, the study explores CRISPR's microbial origins, outlines therapeutic applications, examines technical and ethical barriers, and proposes conceptual models for guiding its future in biomedical innovation.

**Research Questions and Hypotheses**

This study seeks to answer the research question: *How has CRISPR-Cas9 transitioned from a bacterial immune defense to a programmable genome-editing tool?* This question is clear, focused, and relevant, as it highlights the growing role of CRISPR-Cas9 in modern therapeutic innovation. The independent variable is the application of CRISPR-Cas9 as a programmable genome-editing platform. In contrast, the dependent variable is the effectiveness and feasibility of its biomedical outcomes, including precision, delivery efficiency, and therapeutic potential.

*We hypothesize that:*

- *If CRISPR-Cas9 is applied with improved accuracy and delivery methods*, it will enable more effective and targeted treatments for genetic disorders, since accurate DNA modification is essential for therapeutic success [1], [3].

- *Incorporating advanced techniques such as base editing and prime editing will further increase the accuracy and clinical feasibility of CRISPR-Cas9,* as these methods reduce reliance on double-stranded DNA breaks [4], [6].

- *Ethical, governance, and accessibility challenges will remain major barriers to responsible clinical adoption,* underscoring the need for careful oversight and equitable implementation.

These hypotheses define clear variables, establish logical relationships, and remain concise and theoretically grounded.

## Literature Review

### Bacterial Origins and Defense Mechanism:

CRISPR systems function as bacterial immune defenses by storing viral DNA sequences to recognize and destroy future infections. Guided by RNA molecules, Cas9 cleaves matching DNA, revealing a naturally precise DNA-targeting mechanism [1], [2].




**Figure 1.** Illustration of the general CRISPR–Cas9 mechanism, shown here using Streptococcus pyogenes (a Gram-positive bacterium) as an example. The process involves three main phases: adaptation (integration of viral DNA into the CRISPR array), expression (transcription and Cas9–gRNA complex formation), and interference (target recognition and cleavage leading to viral DNA inactivation).

### Stage 1: Adaptation (Memory Acquisition)

Upon phage invasion, the Cas1–Cas2 *integrase (enzyme that inserts viral DNA fragments into the CRISPR array)* selects short *protospacers (viral DNA fragments)* from foreign DNA—typically adjacent to a *PAM (protospacer-adjacent motif, a short recognition sequence)* so that the memory will be targetable later, and inserts them leader-proximally into the CRISPR array. The leader-end integration duplicates the bordering repeat (via host DNA repair) so the array maintains its repeat–spacer–repeat architecture, creating a chronological record of past infections that distinguishes self from non-self during future encounters. This stage rewrites DNA (the genome) but does not yet produce any effector complex [1], [2].

### Stage 2: Expression (Guide Formation and RNP Assembly)

The updated CRISPR array is transcribed as a single *pre-crRNA (precursor CRISPR RNA)* that contains all repeats and spacers. In type II systems (e.g., SpCas9), *tracrRNA (trans-activating CRISPR RNA)* base-pairs with the repeat hairpins of the pre-crRNA and, together with *RNase III (an RNA-cutting enzyme)*, processes it into individual crRNAs. Cas9 then binds the *crRNA–tracrRNA duplex (or an engineered sgRNA, single guide RNA)* to form the ribonucleoprotein effector that carries one spacer "address" for target search. This stage converts the stored DNA memories into RNA guides that program Cas9 specificity [1], [2].

### Stage 3: Interference (Target Recognition and Cleavage)

When the bacterium is invaded again by the same virus, the Cas9–gRNA complex patrols the incoming viral DNA by first searching for PAMs (short recognition motifs such as 5′-NGG-3′ for SpCas9). PAM binding triggers local strand separation, allowing the spacer sequence to check for complementarity and form an R-loop (a DNA–RNA hybrid structure). A correct PAM and spacer match activate Cas9's HNH (target-strand cutting) and RuvC (non-target-strand cutting) nuclease domains, cleaving both strands ~3 bp upstream of the PAM and thereby disabling the invading viral genome. This PAM-gated, two-checkpoint logic (PAM → base-pairing) both accelerates target search and protects the host CRISPR array, which lacks PAM sequences. However, imperfect matching can sometimes lead to off-target cleavage—a key consideration in biotechnology and therapeutic applications [1], [2], [5], [6].

### Transition to Genome Editing:

In 2012, scientists demonstrated that this system could be reprogrammed for targeted genome editing, marking a transformative moment in molecular biology [3]. By designing synthetic guide RNAs, researchers could direct Cas9 to almost any DNA sequence, enabling controlled gene modifications. This adaptation positioned CRISPR-Cas9 as a simpler and more flexible alternative to earlier gene-editing tools such as ZFNs and TALENs [4].

### Biomedical Applications:

Following the demonstration of its programmability, CRISPR-Cas9 rapidly became a cornerstone of modern biomedical research and therapy. Its ability to induce precise, targeted DNA modifications has enabled scientists to explore treatment strategies for a wide range of genetic diseases. One major application involves ex vivo editing of hematopoietic stem cells to treat sickle cell disease, where patient-derived cells are modified outside the body to correct the mutation before being reintroduced [5], [8]. Another key area is immune cell engineering, where CRISPR-Cas9 is used to modify T cells for more effective cancer immunotherapy, improving the ability of the immune system to detect and destroy tumor cells

[6]. Additionally, in vivo gene editing is being explored to correct mutations directly within the body, such as targeting retinal cells to treat inherited blindness [7]. Clinical trials across these domains demonstrate that CRISPR-Cas9 is not only a research tool but also a practical therapeutic platform capable of addressing previously untreatable disorders. Furthermore, the development of base editing and prime editing technologies builds upon the original CRISPR-Cas9 system, enhancing editing precision and reducing unintended DNA breaks [3], [4]. These innovations expand the clinical possibilities of gene therapy while addressing some of the system's earlier technical limitations. Together, these applications illustrate how a mechanism that once protected bacteria from viruses has been transformed into a versatile engine for biomedical innovation and personalized medicine.

**Challenges and Ethical Considerations:**

Despite its promise, significant barriers remain. Off-target mutations pose safety risks, while delivering CRISPR components efficiently into human cells remains technically challenging [9]. Ethical and regulatory concerns, including debates over germline editing and equitable access, further complicate clinical translation. Moreover, emerging approaches such as base and prime editing aim to improve precision and minimize unintended effects, though their long-term impact is still being evaluated [10].

**Gaps in Current Literature:**

While numerous studies have examined CRISPR-Cas9's mechanism and individual therapeutic applications, few have provided an integrated theoretical perspective on its overall transition from microbial defense to biomedical innovation. Existing work tends to focus narrowly on either molecular details or specific diseases, overlooking the broader conceptual transformation. Addressing this gap, the present study synthesizes current knowledge into a theoretical framework that connects CRISPR's origins, technological evolution, and therapeutic potential.

**Methodology**

This study adopts a *qualitative* theoretical methodology to investigate how CRISPR-Cas9 has evolved from a bacterial adaptive immune mechanism into a powerful genome-editing platform in modern biomedicine. Relevant scientific literature—including peer-reviewed journal articles, clinical trial reports, and authoritative reviews—is systematically collected and analyzed to trace key developments in CRISPR-Cas9 research. The methodology focuses on synthesizing existing findings into conceptual models that illustrate the defense mechanism in bacteria, the gene-editing process, and its translation into therapeutic applications. Sources are selected based on their credibility, recency, and relevance to bacterial immunity, molecular biology, and biomedical innovation. This structured approach enables a comprehensive understanding of both the scientific foundations and clinical implications of CRISPR-Cas9 without the need for experimental procedures.

**Experimental Setup:**

As this study is theoretical, the experimental setup involves constructing a detailed annotated diagram to illustrate the CRISPR-Cas9 bacterial defensive immunity mechanism and its adaptation for biomedical innovation. The diagram is designed to trace key stages—spacer acquisition, crRNA formation, Cas9 targeting, and DNA cleavage—alongside the scientific modifications that enable its use as a programmable genome-editing tool in human cells. This conceptual model serves as the analytical framework for understanding how a naturally occurring immune mechanism in bacteria has been transformed into a versatile platform for gene therapy and clinical applications.

**Data Collection:**

As this research is theoretical, data collection involved gathering information from peer-reviewed scientific literature, clinical reports, and credible online databases. Sources were selected based on their relevance to CRISPR-Cas9 bacterial immunity, genome-editing mechanisms, and biomedical applications. Preference was given to recent publications and authoritative reviews to ensure accuracy and up-to-date perspectives. Key concepts from these sources were synthesized to construct annotated diagrams and conceptual frameworks that form the analytical basis of the study.

**Data Analysis:**

Collected information was analyzed qualitatively through thematic synthesis and conceptual modeling. Scientific literature on CRISPR-Cas9 was categorized into key themes, including bacterial immunity, gene-editing mechanisms, biomedical applications, and associated challenges. Findings from these themes were integrated to construct annotated diagrams and frameworks that illustrate the functional pathway of CRISPR-Cas9 and its transition from a natural defense system to a therapeutic genome-editing platform. This analytical approach enables a clear understanding of both the scientific basis and the innovative applications of CRISPR-Cas9 without relying on experimental data.

**Timeline:**

- *Week 1:* Choose and finalize the topic, set objectives, and collect relevant references about CRISPR-Cas9 bacterial immunity and its applications.
- *Week 2:* Read and analyze the sources, highlight key points, and plan how to explain the mechanism and transition clearly.
- *Week 3:* Create and annotate the diagram showing the bacterial defense mechanism and how it's adapted for biomedical innovation. Start drafting the sections.
- *Week 4:* Revise the content, refine the diagram, check references, and finalize everything for submission.

**Conclusion**

In conclusion, this study examines how CRISPR-Cas9, which began as a bacterial immune defense, has developed into a powerful tool for modern biomedical innovation. Through reviewing scientific literature and creating a clear diagram, the research explains the main stages of this transition—from how bacteria use CRISPR-Cas9 to defend against viruses to how scientists adapted it for targeted genome editing in human cells. This transformation has opened the door to new ways of treating genetic diseases, improving therapies, and advancing personalized medicine. However, challenges such as safe delivery, off-target effects, and ethical questions still need careful attention. Ultimately, CRISPR-Cas9 demonstrates how insights from natural biological systems can drive transformative breakthroughs in science and medicine.

**Reference**

[1] M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier, “A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity,” Science, vol. 337, no. 6096, pp. 816–821, 2012, doi: 10.1126/science.1225829.

[2] J. A. Doudna and E. Charpentier, “The new frontier of genome engineering with CRISPR-Cas9,” Science, vol. 346, no. 6213, p. 1258096, 2014, doi: 10.1126/science.1258096.

[3] A. C. Komor, Y. B. Kim, M. S. Packer, J. A. Zuris, and D. R. Liu, “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage,” Nature, vol. 533, pp. 420–424, 2016, doi: 10.1038/nature17946.

[4] A. V. Anzalone et al., “Search-and-replace genome editing without double-strand breaks or donor DNA,” Nature, vol. 576, pp. 149–157, 2019, doi: 10.1038/s41586-019-1711-4.

[5] C. Guo, J. Huang, and A. Yu, “Off-target effects in CRISPR/Cas9 gene editing,” Frontiers in Bioengineering and Biotechnology, vol. 11, p. 1210483, 2023, doi: 10.3389/fbioe.2023.1210483.

[6] T. Li, Y. Shu, X. Tian, and X. Wang, “CRISPR/Cas9 therapeutics: progress and prospects,” Signal Transduction and Targeted Therapy, vol. 8, no. 1, p. 124, 2023, doi: 10.1038/s41392-023-01314-y.

[7] E. A. Pierce et al., “Gene editing for CEP290-associated retinal degeneration (EDIT-101) — clinical results,” New England Journal of Medicine, vol. 390, pp. 415–427, 2024, doi: 10.1056/NEJMoa2304148.

[8] J. Frangoul et al., “Exagamglogene autotemcel for severe sickle cell disease: clinical outcomes,” New England Journal of Medicine, vol. 390, pp. 331–343, 2024, doi: 10.1056/NEJMoa2300099.

[9] K. Chen et al., “Lung and liver editing by lipid-nanoparticle delivery of a CRISPR genome editor,” Nature Biotechnology, vol. 42, pp. 188–197, 2024, doi: 10.1038/s41587-023-02054-6.

[10] World Health Organization, Human genome editing: recommendations and a framework for governance. Geneva: WHO, 2021. [Online]. Available: https://www.who.int/publications/i/item/9789240030381

Pawarate_Vhaiprom_CRISPRCas9_IARCO2025 - Pawarate Vhaiprom.pdf

ORIGINALITY REPORT

| 13% | 7% | 12% | 0% |
| --- | --- | --- | --- |
| SIMILARITY INDEX | INTERNET SOURCES | PUBLICATIONS | STUDENT PAPERS |

PRIMARY SOURCES

| | | |
| --- | --- | --- |
| 1 | Aftab Ahmad, Nayla Munawar, Baohong Zhang. "Gene-Edited Crops - The CRISPR Solution for Global Food Security", CRC Press, 2025<br>Publication | 2% |
| 2 | www.ijisrt.com<br>Internet Source | 2% |
| 3 | hal-pasteur.archives-ouvertes.fr<br>Internet Source | 1% |
| 4 | Urfa Khairatun Hisan, Muhammad Miftahul Amri. "Recommendation of precision medicine application in Indonesia from multiple perspective: a review", International Journal of Public Health Science (IJPHS), 2023<br>Publication | 1% |
| 5 | acopen.umsida.ac.id<br>Internet Source | 1% |
| 6 | bura.brunel.ac.uk<br>Internet Source | 1% |
| 7 | epub.ub.uni-muenchen.de<br>Internet Source | 1% |
| 8 | Miller, Eric W., Tram N. Cao, Kathryn J. Pflughoeft, and Paul Sumby. "RNA-mediated regulation in Gram-positive pathogens: an | <1% |

overview punctuated with examples from the group A S treptococcus : RNA-mediated regulation in Gram-positives", Molecular Microbiology, 2014.
Publication

| | | |
|---|---|---|
| 9 | Rumiana Tenchov, Qiongqiong Angela Zhou. "Molecular Paleontology Meets Drug Discovery: The Case for De-Extinct Antimicrobials", American Chemical Society (ACS), 2025<br>Publication | <1 % |
| 10 | www.mdpi.com<br>Internet Source | <1 % |
| 11 | Winston X. Yan, Shaorong Chong, Huaibin Zhang, Kira S. Makarova, Eugene V. Koonin, David R. Cheng, David A. Scott. "Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein", Molecular Cell, 2018<br>Publication | <1 % |
| 12 | janusnet-ojs.autonoma.pt<br>Internet Source | <1 % |
| 13 | Joy A. Cavagnaro, Mary Ellen Cosenza. "Translational Medicine - Optimizing Preclinical Safety Evaluation of Biopharmaceuticals", CRC Press, 2021<br>Publication | <1 % |
| 14 | Navdeep Kaur, Shubham Sharma, Mirza Hasanuzzaman, Pratap Kumar Pati. "Genome Editing: A Promising Approach for Achieving Abiotic Stress Tolerance in Plants", International Journal of Genomics, 2022 | <1 % |

Publication

| | | |
|---|---|---|
| 15 | Nikhil Jarunde. "Cognitive Enhancement and Derivatives Trading: Will Neuralink Create a New Class of Super-Traders?", Proceedings of The International Conference on Research in Management and Economics, 2025<br>Publication | <1 % |
| 16 | Alok Kumar Singh, Sivaprakash Ramalingam, Desirazu N. Rao, Srinivasan Chandrasegaran. "Genome Editing Revolution in Life Sciences", Resonance, 2021<br>Publication | <1 % |
| 17 | www.broadinstitute.org<br>Internet Source | <1 % |
| 18 | www.science.org<br>Internet Source | <1 % |
| 19 | drpress.org<br>Internet Source | <1 % |
| 20 | www.biorxiv.org<br>Internet Source | <1 % |

| | | | |
|---|---|---|---|
| Exclude quotes | On | Exclude matches | Off |
| Exclude bibliography | Off | | |